Alveolar Soft Part Sarcoma Clinical Trials

5 recruiting

Alveolar Soft Part Sarcoma Trials at a Glance

7 actively recruiting trials for alveolar soft part sarcoma are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Los Angeles, Pittsburgh, and Bethesda. Lead sponsors running alveolar soft part sarcoma studies include National Cancer Institute (NCI), Advenchen Laboratories, LLC, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Browse alveolar soft part sarcoma trials by phase

Treatments under study

About Alveolar Soft Part Sarcoma Clinical Trials

Looking for clinical trials for Alveolar Soft Part Sarcoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alveolar Soft Part Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alveolar Soft Part Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

SarcomaAlveolar Soft Part SarcomaUndifferentiated Pleomorphic Sarcoma+1 more
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT04332874
Recruiting
Phase 2

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

Alveolar Soft Part Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.33 enrolled15 locationsNCT07548177
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 2

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Metastatic Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaAdvanced Alveolar Soft Part Sarcoma+2 more
National Cancer Institute (NCI)27 enrolled13 locationsNCT05333458
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting
Phase 3

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

LeiomyosarcomaSynovial SarcomaAlveolar Soft Part Sarcoma
Advenchen Laboratories, LLC325 enrolled24 locationsNCT03016819
Recruiting
Not Applicable

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Soft Tissue SarcomaDesmoplastic Small Round Cell TumorClear Cell Sarcoma+7 more
Institut Claudius Regaud400 enrolled20 locationsNCT03967834